| pubmed-article:21502544 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0812241 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C1537502 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0995188 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:21502544 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:21502544 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:21502544 | pubmed:dateCreated | 2011-5-19 | lld:pubmed |
| pubmed-article:21502544 | pubmed:abstractText | The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken. | lld:pubmed |
| pubmed-article:21502544 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21502544 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21502544 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21502544 | pubmed:month | May | lld:pubmed |
| pubmed-article:21502544 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:CunninghamDav... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:KöhneClaus-He... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:CiardielloFor... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:CascinuStefan... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:CelikIlhanI | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:RougierPhilip... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:TejparSabineS | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:LángIstvánI | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:MaurelJoanJ | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:NowackiMarek... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:ZubelAngelaA | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:FolprechtGunn... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:SchlichtingMi... | lld:pubmed |
| pubmed-article:21502544 | pubmed:author | pubmed-author:ShchepotinIgo... | lld:pubmed |
| pubmed-article:21502544 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21502544 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:21502544 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21502544 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21502544 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21502544 | pubmed:pagination | 2011-9 | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:meshHeading | pubmed-meshheading:21502544... | lld:pubmed |
| pubmed-article:21502544 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21502544 | pubmed:articleTitle | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. | lld:pubmed |
| pubmed-article:21502544 | pubmed:affiliation | University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be | lld:pubmed |
| pubmed-article:21502544 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21502544 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21502544 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21502544 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21502544 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
